# EDGAR Filing Document

**Accession Number:** 0001740053
**File Stem:** 0001740053-23-000002
**Filing Date:** 2023-1
**Character Count:** 7407
**Document Hash:** ca31e2f8a83303da3fa2b881e7117af3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001740053-23-000002.hdr.sgml**: 20230123

**ACCESSION NUMBER**: 0001740053-23-000002

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230123

**DATE AS OF CHANGE**: 20230123

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALBIREO PHARMA, INC.
- **CENTRAL INDEX KEY:** 0001322505
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-83386
- **FILM NUMBER:** 23543255

**BUSINESS ADDRESS:**
- **STREET 1:** 10 POST OFFICE SQUARE
- **STREET 2:** SUITE 502 SOUTH
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109
- **BUSINESS PHONE:** 857-415-4774

**MAIL ADDRESS:**
- **STREET 1:** 10 POST OFFICE SQUARE
- **STREET 2:** SUITE 502 SOUTH
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biodel Inc
- **DATE OF NAME CHANGE:** 20050331
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chicago Capital, LLC
- **CENTRAL INDEX KEY:** 0001740053
- **IRS NUMBER:** 823400556
- **STATE OF INCORPORATION:** IL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 135 S LASALLE ST
- **STREET 2:** SUITE 4200
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60603
- **BUSINESS PHONE:** 3124292335

**MAIL ADDRESS:**
- **STREET 1:** 135 S LASALLE ST
- **STREET 2:** SUITE 4200
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60603

```

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. ___)*
ALBIREO PHARMA, INC
ALBIREO PHARMA, INC.
(Name of Issuer)
COMMON STOCK, PAR VALUE $.001 PER SHARE
(Title of Class of Securities)
01345P106
(CUSIP Number)
December 31, 2022
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

	[_]  Rule 13d-1(b)

	[x]  Rule 13d-1(c)

	[_]  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting persons
initial filing on this form with
respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior
cover page.

The information required in the remainder of this cover page shall not be
deemed to be filed for the purpose of Section 18 of the Securities E
xchange Act of 1934 (Act) or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).

SCHEDULE 13G
CUSIP No.
01345P106

1
Names of Reporting Persons

Chicago Capital LLC
2
Check the appropriate box if a member of a Group (see instructions)

(a)
(b)
3
Sec Use Only

4
Citizenship or Place of Organization

Illinois
Number of Shares Beneficially Owned by Each Reporting Person With:

5
  Sole Voting Power

  1,362,484

6
  Shared Voting Power

  -0-

7
  Sole Dispositive Power

  1,362,484

8
  Shared Dispositive Power

  -0-
9
Aggregate Amount Beneficially Owned by Each Reporting Person

1,362,484
10
Check box if the aggregate amount in row (9) excludes certain
shares (See Instructions)

[ ]
11
Percent of class represented by amount in row (9)

6.6%
12
Type of Reporting Person (See Instructions)

IA

Item 1.
(a)	Name of Issuer:
       Albireo Pharma Inc  (the Issuer).
(b)	Address of Issuers Principal Executive Offices:

       53 State Street, 19th Floor

       Boston, MA 02109
Item 2.
(a) Name of Person Filing:
Chicago Capital LLC
(b) Address of Principal Business Office or, if None, Residence:
135 South LaSalle Street, Suite 4200
	Chicago, IL 60603
(c) Citizenship:
Illinois
(d) Title and Class of Securities:
common stock, par value $0.001 per share (Common Stock)
(e) CUSIP No.:
	01345P106
Item 3. 	If this statement is filed pursuant to 240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a)	[_]	Broker or dealer registered under Section 15 of the Act;
(b)	[_]	Bank as defined in Section 3(a)(6) of the Act;
(c)	[_]	Insurance company as defined in Section 3(a)(19) of the Act;
(d)	[_]	Investment company registered under Section 8 of the
Investment Company Act of 1940;
(e)	[X]	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f)	[_]	An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F);
(g)	[_]	A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
(h)	[_]	A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
(i)	[_]	A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment Company Act of 1940;
(j)	[_]	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
(k)	[_]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a
non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please
specify
the type of institution: ____
Item 4.	Ownership
(a)	Amount Beneficially Owned:
	1,362,484
 (b)	Percent of Class:
       6.6%
 (c)	Number of shares as to which such person has:
	(i)	Sole power to vote or to direct the vote:
		1,362,484
	(ii)	Shared power to vote or to direct the vote:
		-0-
(iii) Sole power to dispose or to direct the disposition of:
1362484
(iv) Shared power to dispose or to direct the disposition of:
-0-
Item 5.	Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date
hereof the
reporting person has ceased to be the beneficial owner of more than
five percent
of the class of securities, check the following [  ].
Item 6.	Ownership of more than Five Percent on Behalf of Another Person.
	Not applicable
Item 7.	Identification and classification of the subsidiary which acquired the
security being reported on by the parent holding company or control person.
	Not applicable
Item 8.	Identification and classification of members of the group.
	Not applicable
Item 9.	Notice of Dissolution of Group.
	Not applicable
Item 10.	Certifications.

SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
By: Chicago Capital LLC,
its Chief Compliance Officer
Dated01212023
/s/Stacey Sargent
Name: Stacey Sargent
Title: Chief Compliance Office
Name/Title
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative.  If the statement is
signed on behalf of a person by his authorized representative (other than
an executive officer or general partner of this filing person), evidence
of the representative's authority to sign on behalf of such person shall
be filed with the statement, provided, however, that a power of attorney
for this purpose which is already on file with the Commission may be
incorporated by reference.  The name and any title of each person who
signs the statement shall be typed or printed beneath his signature.
Attention:  Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).
Page 2 of 5

1297544.3

```